SAN DIEGO, Apr 27, 2010 (BUSINESS WIRE) --Illumina, Inc. (NASDAQ:ILMN) today announced that the Company will webcast its presentations at two upcoming investment conferences.
Illumina will webcast its presentation at the Deutsche Bank Securities Annual Health Care Conference in Boston, Massachusetts on Tuesday, May 4, 2010. The live webcast is scheduled to begin at 8:00 a.m. ET and will feature a brief overview of the company by Christian Henry, senior vice president, chief financial officer and general manager of Life Sciences, followed by a question and answer session. Illumina will also webcast its presentation at the Baird Growth Stock Conference in Chicago, Illinois on Wednesday, May 19, 2010. The live webcast is scheduled to begin at 12:15 p.m. ET and will feature an overview of the company by Christian Henry, followed by a question and answer session.
These live webcasts can be accessed under the "Corporate/Investor Information" tab of Illumina's web site at http://www.illumina.com.
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
Forward-Looking Statements
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
+858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Sr. Manager, Public Relations
+858-882-6822
wgrabill@illumina.com
